What Is PT-141?

PT-141 (bremelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that acts on melanocortin receptors in the central nervous system to increase sexual arousal. It was developed by Palatin Technologies and is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. That makes it the only peptide in this group with a current, active US drug approval.

The mechanism is distinct from all other sexual dysfunction drugs on the market. PDE5 inhibitors like sildenafil work peripherally by increasing blood flow to genital tissue. PT-141 works centrally, activating MC4R receptors in the hypothalamus to increase sexual desire itself, not just the physical response. This central mechanism is why it affects both women and men and why it produces subjective arousal rather than just vascular changes.

PT-141 was originally developed from Melanotan II (MT-II), a tanning peptide. Researchers studying MT-II's side effects in humans noticed spontaneous sexual arousal as a consistent off-target effect. That observation drove the pivot to PT-141 as a targeted sexual function compound.

What Does the Research Say?

Evidence level: Strong — PT-141 / bremelanotide has completed Phase II and Phase III randomized controlled trials in humans, including the pivotal studies that supported FDA approval for HSDD in premenopausal women in June 2019. Human efficacy and safety data exists at a level well above most peptides in this category.

Animal Studies

Animal pharmacology for PT-141 was conducted primarily in rodent models as part of Palatin Technologies' preclinical program. Studies in rats and primates demonstrated that MC4R agonism in the central nervous system produced male mounting behavior and female receptivity increases, confirming the central arousal mechanism. These findings were consistent and helped justify the human development program.

Human Studies

PT-141 has a meaningful body of human RCT data, which is unusual in this category.

For women with HSDD, two Phase III pivotal trials supported FDA approval. The RECONNECT studies enrolled premenopausal women with acquired, generalized HSDD and measured changes in the number of satisfying sexual events and sexual desire scores over 24 weeks. Both trials showed statistically significant improvements versus placebo on the primary endpoints. The FDA approved Vyleesi (bremelanotide) for HSDD in premenopausal women in June 2019.

Earlier Phase II work by Clayton et al. and Simon et al. also documented efficacy signals in women with HSDD, contributing to the regulatory pathway. These Phase II studies used both intranasal and subcutaneous delivery; the transition to subcutaneous-only in Phase III reflected better bioavailability and reduced nausea with the injection route.

Studies in men with erectile dysfunction were conducted in Phase II. Results showed improvements in erectile function measures, with some data suggesting benefit for men with ED who did not respond to PDE5 inhibitors. This program was not pursued to FDA approval for men, and Vyleesi is approved only for premenopausal women with HSDD.

Community and Anecdotal Reports

PT-141 has significant use in male biohacking and sexual performance communities, where it is often used off-label for enhanced sexual response, increased libido, and as a complement to or substitute for PDE5 inhibitors. Users report onset of arousal effects within one to two hours of injection.

Nausea is consistently reported as the most significant side effect and the primary reason users stop using it. Some users report transient flushing and headache. The reports on efficacy for arousal are consistent with the clinical trial data, which is unsurprising given that the clinical data is for the same mechanism.

Common Uses

Hypoactive Sexual Desire Disorder (HSDD)

This is the only FDA-approved indication. HSDD is defined as persistently low sexual desire that causes personal distress, without an identifiable medical or psychiatric cause and not attributable to relationship problems. The RECONNECT trials were conducted specifically in this population and represent the strongest evidence PT-141 has.

Erectile Dysfunction

Phase II data suggests PT-141 can improve erectile function, including in some men who don't respond to PDE5 inhibitors. This was not pursued to FDA approval and is off-label use. The central mechanism (desire-based) rather than peripheral (blood flow-based) may explain why it reaches patients PDE5 inhibitors don't.

General Sexual Enhancement

Off-label use for enhanced arousal, libido, and sexual response in people without a diagnosed disorder is common in community contexts. This is not an indication studied in clinical trials. The clinical mechanism would still apply, but the population studied in trials is different.

Delivery Methods

Subcutaneous Injection

The approved delivery method for Vyleesi is subcutaneous injection using a prefilled autoinjector. The injection is given 45 minutes before anticipated sexual activity. This is the route validated in Phase III trials and reflected in the FDA prescribing information.

Earlier clinical work used intranasal delivery, which showed efficacy but had higher rates of nausea and less predictable absorption. The Phase III program switched to subcutaneous delivery specifically to reduce nausea and improve bioavailability consistency.

Community users with compounded PT-141 typically use the same subcutaneous route with similar timing.

PEPVi does not provide dosing guidance. Dosing decisions should be made in consultation with a qualified healthcare provider.

Safety and Side Effects

The FDA prescribing information for Vyleesi documents the safety profile from the pivotal trials. Nausea is the most common adverse effect, reported in roughly 40% of trial participants. It is usually mild to moderate and transient. Flushing (facial warmth and redness) is reported in about 20%. Headache and injection site reactions are also common.

Transient blood pressure increases (both elevation and decrease) were observed in the trials. The prescribing information includes a warning to avoid use in patients with cardiovascular disease, recommending a blood pressure check before and monitoring after use.

The FDA label also notes that bremelanotide caused hyperpigmentation — darkening of the face, gums, and breasts — with long-term daily use in clinical studies. Vyleesi is approved for as-needed use, not daily use, partly to address this concern. Users taking PT-141 frequently or in higher doses than prescribed should be aware of this risk.

The melanocortin system also affects skin pigmentation broadly. PT-141's relationship to the tanning peptide Melanotan II raises reasonable questions about long-term effects on melanocyte activity at higher doses or frequencies than studied. No data establishes safety for daily or frequent use.

PT-141 / bremelanotide is FDA-approved as Vyleesi for HSDD in premenopausal women. This makes it unique among the peptides on this site: a licensed pharmaceutical product.

The FDA approval covers the commercial Vyleesi formulation. Compounded versions of bremelanotide are subject to the same 503A/503B compounding restrictions that affected other peptides. The FDA's position is that compounded versions of approved drugs require specific justification and are generally not permitted when a commercially manufactured version is available.

PT-141 is one of the 12 peptides targeted in the current reclassification process. For the regulatory context, see What RFK's Peptide Reclassification Means for You.

International status varies. Bremelanotide is not approved outside the US as of this writing, though it has been investigated in several international clinical programs.

Frequently Asked Questions

Yes. Vyleesi is the FDA-approved brand name for bremelanotide, which is the generic name for PT-141. The compound is identical. The distinction is between the FDA-approved commercial product and compounded versions, which have different regulatory standing.

Phase II data showed improvements in erectile function measures in men, including some who didn't respond to PDE5 inhibitors. The FDA did not approve it for men, so this is off-label use. The central arousal mechanism is not sex-specific; whether the Phase III program in women would have replicated in men was simply not tested at that scale.

PDE5 inhibitors (sildenafil, tadalafil) work peripherally by increasing blood flow to genital tissue when aroused. PT-141 works centrally by activating the neural circuits for sexual desire itself. PT-141 can produce arousal in the absence of any physical stimulation; PDE5 inhibitors enhance the physical response to stimulation but don't generate desire. They can be used together, though this has not been formally studied.

Nausea (about 40% in trials), flushing (about 20%), and headache. The nausea is the main reason people stop using it. Taking the injection after eating rather than fasted reduces nausea in community experience, though this was not formally tested against the prescribing information's recommended timing.

Learn More

Sources

  1. Kingsberg SA, Clayton AH, Portman D, et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials." Obstetrics & Gynecology, 2019. — The RECONNECT Phase III pivotal trials supporting FDA approval; primary efficacy and safety data in premenopausal women with HSDD.

  2. Clayton AH, Althof SE, Kingsberg S, et al. "Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial." Women's Health, 2016. — Phase II dose-finding data supporting the Phase III program; documented efficacy in HSDD with subcutaneous administration.

  3. FDA. "Vyleesi (bremelanotide) prescribing information." Palatin Technologies / AMAG Pharmaceuticals, 2019. — FDA-approved prescribing information; authoritative source for approved indication, dosing, and safety profile.